Date:11/17/2010

rized by airflow obstruction, which leads to the hallmark symptoms of COPD - chronic cough, chest tightness, shortness of breath, increased effort to breathe and increased mucus production. Over time, patients with COPD suffer from shortness of breath so severe that it interferes with the most basic daily activities including sleeping, talking, and even dressing.

About World COPD DayWorld COPD Day is an annual event organized by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) to improve awareness and care of chronic obstructive pulmonary disease (COPD) around the world. World COPD Day 2010 will take place on November 17 around the theme "2010 - The Year of the Lung: Measure your lung health - Ask your doctor about a simple breathing test called spirometry."About the ResearchIn-home interviews were conducted with 16 COPD patients in Phoenix, AZ, and New York, NY.  The goals of the interviews were to uncover first-hand insights into how the disease impacts patient lives; understand who the COPD sufferer is, including lifestyle elements and life goals that may be compromised because of COPD; and to identify perceptions about COPD and participants' core emotions in living with the disease.

Respondents had a range of disease severity and included a representative mix of respondents in terms of age, income level, race, and education.

All research participants had been diagnosed with COPD, including chronic bronchitis and/or emphysema. The in-home setting also enabled engagement with patient family members to see how living with the condition affects the caregiver.  

GlaxoSmithKline – one of the world's leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information go to us.gsk.com'/>"/>

SOURCE GlaxoSmithKline Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients
2. Tengion Advances Clinical Trial for Neo-Urinary Conduit™ in Bladder Cancer Patients
3. Mortality Data Presented for Patients Treated with Effient® Who Underwent Isolated Coronary Artery Bypass Surgery
4. Mortality Data Presented for Patients Treated with Efient®/Effient® (Prasugrel) Who Underwent Isolated Coronary Artery Bypass Surgery
5. First-Line Use of Abilify Has More Than Doubled Over the Past Year for the Treatment of Newly-Diagnosed Patients in Bipolar Disorder
6. NIH-Funded Study Is First to Demonstrate Increased Long-Term Survival With Favorable Neurologic Function Among Patients Receiving CPR Using ACSI ResQPump™ and ResQPOD® CPR Devices
7. NT-proBNP Guided Therapy Keeps Heart Failure Patients out of the Hospital Through a Reduction in Cardiovascular Events
8. New Study: Overuse of Combination Drug Therapy in Patients with Mild Asthma Leads to Increased Costs
9. Sangart, Inc. Receives U.S. Orphan Drug Designation for use of MP4CO in Patients with Sickle Cell Disease
10. Adding INSPRA® (eplerenone) to Standard Therapy Significantly Reduces the Risk of CV Mortality and Morbidity in Patients With Chronic Heart Failure With Mild Symptoms, Study Shows
11. Study Published in New England Journal of Medicine Shows Nplate® Significantly Reduces Treatment Failure and Splenectomy Rate in Patients With Chronic ITP